Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with a US loss of exclusivity now anticipated in 2036 rather than the previous estimate of 2033 due to generic litigation settlements.

Yeztugo’s market potential was also emphasized by the company, which stated that the pre-exposure prophylaxis market might be “much larger than currently appreciated,” possibly reaching $15–20 billion.

Even so, Gilead Sciences, Inc. (NASDAQ:GILD) has been under pressure for certain other products. A Phase 3 trial for HR+/HER2-negative metastatic breast cancer revealed that Gilead Science’s cancer medication Trodelvy failed to fulfill its primary objective. The ASCENT-07 trial, which compared Trodelvy against chemotherapy, was unable to meet its main objective of progression-free survival.

Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally.

While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.